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Abstract 
Background and aims: Metabolic syndrome (MS) might influence the course of atrial 
fibrillation (AF) similarly to diabetes (DM). Aim of this research is to evaluate the quality 
of life, disease burden and medication adherence of patients with different metabolic 
states. Material and methods: A cross-sectional study of Latvian Center of Cardiology 
Arrhythmology Department patients with AF, sorting patients in 3 categories according 
to the National Institutes for Health guidelines criteria for MS. Results: From 133 
patients, 51 were in metabolically healthy (MH) group, 58 in MS group and 24 had DM. 
Average age was 62.59 in MH, 67.59 in MS and 66.25 in DM group. Most common form 
of AF was persistent - MH 49%, MS 65.5%, DM 75%. Best EHRA median value was 
observed in DM group (29.2% reporting mild symptoms).  Majority of patients had 1-2 
comorbidities in MH and MS group and 3-5 in the DM group, with almost all patients 
using 4-9 drugs daily. Conclusions: A similar course of AF was observed in MS and DM 
groups. Since the same molecular pathways are involved, MS should be viewed as a 
cluster of risk factors with a cumulative effect - greater than the effect of a single risk 
factor. 
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Background and aims 
There is a proven link between diabetes and 
atrial fibrillation susceptibility [1,2] bringing up 
the question if other changes in metabolic status 
such as metabolic syndrome are capable of 
influencing the susceptibility, course, treatment 
and outcome of atrial fibrillation. Criteria for 
metabolic syndrome, as defined by National 
Institutes for Health guidelines, [3] - 
hypertension, obesity, decreased levels of high 
density lipo cholesterol, elevated triglycerides 
and elevated blood sugar - are known risk factors 
for atrial fibrillation [4], but most of them are 
studied separately instead of a cluster as they 
appear in the case of metabolic syndrome. 
Which could be very likely generating a 
cumulative effect. With the growing prevalence 
of metabolic syndrome - ranging from 24% of 
population in continental Europe [5] to 78% in 
northern Europe [6] - and atrial fibrillation 
already affecting around 2% of Europe [6], this 
connection should be thoroughly investigated. 
This might prove crucial for understanding and 
treating atrial fibrillation - an illness that is 
predicted to become more prevalent in the aging 
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European population [7], especially considering 
advances in our ability to treat cardiac and other 
chronic diseases.  
Existing data on the association between the 
two is lacking and often contradictory with some 
studies reporting twice the prevalence of atrial 
fibrillation in patients with metabolic syndrome 
compared to patients without [8], yet some 
researchers remain unconvinced [9]. This 
research looks at and compares the quality of 
life, disease burden, lifestyle and medication 
adherence of patients with different metabolic 
status.  
Material and methods 
Study design and patients  
This was a cross-sectional study of Latvian 
Center of Cardiology Arrhythmology 
Department patients who had a confirmed 
diagnosis of atrial fibrillation at the time of 
study. Patients were sorted into 3 categories - 
metabolically healthy or MH (excluding patients 
with uncontrolled thyroid issues), with metabolic 
syndrome or MS and patients with confirmed 
diagnosis of diabetes or DM, without a further 
division of patients with type 1 or type 2 
diabetes. Patients, with the help of an assistant 
available for clarifying unclear questions, were 
asked to fill in a questionnaire regarding their 
quality of life, disease burden, lifestyle and 
medication adherence.  
Laboratory, anthropometric 
and clinical data collection 
Data on medication, polymorbidity and 
blood analysis was collected from medical 
histories. An assistant carried out measurements 
of patients with a calibrated scale, subtracting 
weight of the clothing a patient was wearing. 
Waist measurement was taken without clothing, 
leveling the tape at the belly button and reading 
the measurement after an exhale. BMI was 
calculated by dividing weight in kilograms by 
the square of the height in meters. Patients were 
grouped in the category of metabolic syndrome 
if their waist circumference exceeded 89 cm for 
women and 102 cm for men, triglyceride levels 
at or above 1.7 millimoles per liter, high density 
lipo cholesterol below 1.3 millimoles per liter for 
women and 1.04 for men, blood pressure above 
130/85 mmHg, blood fasting sugar above 5.6 
millimoles per liter or if a patient was taking 
medication to control any of these traits.  
Statistical analysis 
SPSS version 22.0 was utilized for the data 
analysis. P value was considered significant at 
<0.05. One-way ANOVA was used to compare 
means of the groups and Pearson's chi-square 
test for categorical data evaluation. 
Results 
Baseline characteristics of the 133 patients 
can be found in Table 1. 51 were in MH group, 
58 in MS group and 24 had DM. 44% of the 
participants were women, the mean age of 
participants being 64.4 years. There was a 
similar number of smokers in all groups, 
removing smoking as a possible influencer of 
results. 22 of all the patients were acutely 
admitted for hospitalization at the time of the 
study  
Blood pressure analysis reported 27.5% 
patients with hypertension in MH group, 37.9% 
in MS group and 48% in DM group. However, 
the average systolic and diastolic blood pressures 
in each group were similar ranging from 145/94 
mmHg in MH group to 149/90 mmHg in the DM 
group.  
Laboratory findings can be found in Table 2. 
Highest average fasting blood glucose was 
reported in DM group at 8.28 mmol/l, 
metabolically healthy group reported normal 
average blood glucose levels. Average 
cholesterol and LDLH were found in 
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metabolically healthy group, however they also 
had the highest levels of HDLH and lowest 
levels or triglycerides.  
Table 1. Baseline characteristics. A comparison of patient baseline characteristics between all groups showing average 





Diabetes Mellitus All 
Age 62.5 67.5 66.2 64.4 
Female sex (n) 24 26 8 58 
Average BMI 26.7 31.9 36.9 30.8 
Smoker (n) 4 5 2 11 
Acute care (n) 12 7 3 22 
Table 2. Laboratory findings. A comparison of the average glucose, cholesterol, high density lipocholesterol (HDLH), 
low density lipocholesterol (LDLH), triglycerides between the groups of metabolically healthy, metabolic syndrome and 
diabetes mellitus patients. 
 
mmol/l 
Metabolically healthy Metabolic syndrome Diabetes Mellitus 
Average glucose  5 6.17 8.28 
Average cholesterol 5.16 4.43 4.32 
HDLH 1.44 1.27 1.33 
LDLD 3.2 2.5 2.32 
Triglycerides 1.28 1.63 1.84 
Table 3. Life quality measures. A comparison of life quality markers between the groups of metabolically healthy, 
metabolic syndrome and diabetes mellitus patients, showing percentage of persistent atrial fibrillation, number of patients 
with low medication adherence, percentage of patients with high life quality, average EHRA score, average number of 
polymorbidities and drugs used daily. 
 Metabolically healthy Metabolic syndrome Diabetes Mellitus 
Persistent atrial 
fibrillation (%) 
49 65.5 75 
Low medication 
adherence (n) 
4 3 3 
High life quality (%) 5.9 15.5 29.2 
EHRA score 2.65 2.52 2.42 
Average polymorbidities 
(n) 
2.22 2.59 3.96 
Average drugs used daily 
(n) 
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Life quality assessment can be found in table 
3. Most common form of atrial fibrillation was 
persistent - MH 49%, MS 65.5%, DM 75%, with 
MH having the highest incidence of permanent 
AF (7.8%) (p-0.221). There was a similar 
number of patients with self-reported low 
medication adherence in all groups. The lowest 
average life quality and highest EHRA score was 
reported by the MH group, with only 5.9% of the 
group reporting high life quality. Average 
number of polymorbidities and drugs used daily 
was the highest in the DM group.  
Discussions 
This study showed that subjects meeting the 
criteria for metabolic syndrome were more prone 
to complicated course of atrial fibrillation with 
more cases of persistent atrial fibrillation, higher 
number of drugs used daily and more 
comorbidities.  
Type 2 diabetes is an established risk factor 
for atrial fibrillation and some knowledge has 
been gathered on the potential molecular 
mechanisms at play responsible for this 
association [10]. One has to recognize that 
metabolic syndrome also would utilize the same 
molecular pathways, triggering the same cascade 
[11]. 
More research is needed to establish a 
difference in risk for developing atrial 
fibrillation between patients presenting a single 
risk factor for example high blood pressure 
versus patients with metabolic syndrome. In our 
study the metabolically healthy group was 
defined as individuals who did not meet 
necessary number of criteria to classify them as 
having metabolic syndrome, did not have 
diabetes mellitus or thyroid dysfunction, 
however most of these patients had either high 
blood pressure or elevated triglycerides, or low 
density lipo cholesterol. Since even the 
metabolically healthy group usually presented 
with at least one risk factor for atrial fibrillation 
[4,12], our study has observed that a cluster of 
risk factors in the case of metabolic syndrome 
should be looked at as more dangerous than just 
a single risk factor because of its cumulative 
effect. 
Our study had some limitations - the quality 
of life and disease burden were self-reported, 
creating a paradox with metabolically healthy 
people with few comorbidities reporting a lower 
overall life quality than patients with diabetes 
who had a much higher count of comorbidities, 
were much more likely to have persistent atrial 
fibrillation and often presented with heart 
failure. This paradox has been observed in other 
studies too [13], the Finnish Twin Cohort found 
that life satisfaction was not always associated 
with mortality, meaning that otherwise healthy 
adults might rate their symptoms as more 
alarming and burdening than patients who are 
already used to burden of other diseases.  
Conclusions 
Overall patients with MS fared worse than 
MH group, but better than patients with DM, 
showing a correlation between MS and a more 
complicated course of AF similar to that 
associated with DM. Physicians should be aware 
of this when treating a patient with atrial 
fibrillation, as it might influence the course, 
outcome and overall patient satisfaction with the 
received treatment. Diabetes mellitus and 
metabolic syndrome increase the risk of atrial 
fibrillation through the same molecular pathways 
and should be viewed as a cluster of risk factors 
with a cumulative effect which is far greater than 
the effect of a single risk factor. 
Caution must be used in assessing the 
disease burden, because patients presenting with 
other morbidities might under-report their 
symptoms and vice versa.  
 
 
Romanian Journal of Diabetes Nutrition & Metabolic Diseases / Vol. 25 / no. 2 / 2018 169 
Further studies are needed to understand the 
mechanisms at play and to establish other 
possible high-risk groups when it comes to atrial 
fibrillation.  
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